RAYMOND JAMES & ASSOCIATES, INC.1 Case No. 1:20-cv-3028(PKC) Plaintiff, -against- CONFIDENTIALITY ORAMED PHARMACEUTICALS INC., STIPULATION AND PROPOSED PROTECTIVE ORDER Defendant. WHEREAS, the Parties having agreed to the following terms of confidentiality, and the Court having found that good cause exists for the issuance of an appropriately tailored confidentiality order pursuant to Rule 26(c) of the Federal Rules of Civil Procedure, it is hereby ORDERED that the following restrictions and procedures shall apply to the information and documents exchanged by the parties in connection with the pre-trial phase of this action: 1. Counsel for anypartymay designate anydocument or information, in whole or in part, as confidential if counsel determines, in good faith, that such designation is necessary to protect the interests of the client in information that is proprietary, a trade secret or otherwise sensitive non-public information. Information and documents designated by a party as confidential will be stamped“CONFIDENTIAL.” 2. The Confidential Information disclosed will be held and used by the person receiving such information solely for use in connection with theaction. 3. In the event a party challenges another party’s designation of confidentiality, counsel shall make a good faith effort to resolve the dispute, and in the absenceof a resolution, the challenging party may seek resolution by the Court. Nothing in this Protective Order constitutes an admission by any party that Confidential Information disclosed in this case is relevant or admissible. Each party reserves the right to object to the use or admissibility of the Confidential Information. 4. The parties should meet and confer if any production requires a designation of “For Attorneys’or Experts’Eyes Only.” All otherdocuments designated as“CONFIDENTIAL” shall not be disclosed to any person,except: a. The requesting party and counsel, including in-housecounsel; b. Employees of such counsel assigned to and necessary to assist in the litigation; c. Consultants or experts assisting in the prosecution or defense of the matter, to the extent deemed necessary by counsel;and d. The Court (including the mediator, or other person having access to any Confidential Information by virtue of his or her position with theCourt). 5. Prior to disclosing or displaying the Confidential Information to any person, counselmust: a. Informthepersonoftheconfidentialnatureoftheinformationordocuments; b. Inform the person that this Court has enjoined the use of the information or documents by him/her for any purpose other than this litigation and has enjoinedthedisclosureoftheinformationordocumentstoanyotherperson; and c. Require each such person to sign an agreement to be bound by this Order in the form attached as ExhibitA. 6. The disclosure of a document or information without designating it as “Confidential” shall not constitute a waiver of the right to designate such document or information as Confidential Information. If so designated, the document or information shall thenceforth be treatedasConfidentialInformationsubjecttoallthetermsofthisStipulationand Order. 7. Any Personally Identifying Information (“PII”) (e.g., social security numbers, financial account numbers, passwords, and information that may be used for identity theft) exchanged in discovery shall be maintained bythe receivingpartyin a manner that is secure and confidentialandsharedonlywithauthorizedindividualsinasecuremanner. Theproducingparty may specify the minimal level of protection expected in the storage and transfer of its information. In the event the party who received PII experiences a data breach, it shall immediately notify the producing party of same and cooperate with the producing party to address and remedy the breach. Nothing herein shall preclude the producing party from asserting legal claims or constitute a waiver of legal rights and defenses in the event of litigation arising out of the receiving party’s failure to appropriately protect PII from unauthorized disclosure. 8. Pursuant to Federal Rule of Evidence 502, the production of privileged or work- product protected documents or communications, electronically stored information (“ESI”) or information, whether inadvertent or otherwise, shall not constitute a waiver of the privilege or protection from discovery in this case or in any other federal or state proceeding. This Order shall be interpreted to provide the maximum protection allowed by Federal Rule of Evidence 502(d). Nothing contained herein is intended to or shall serve to limit a party’s right to conduct a review of documents, ESI or information (including metadata) for relevance, responsiveness and/or segregation of privileged and/or protected information before production. 9. Notwithstanding the designation of information as “Confidential” in discovery, there is no presumption that such information shall be filed with the Court under seal. The parties shall follow the Court’s procedures for requests for filing underseal. 10. At the conclusion of litigation, Confidential Information and any copies thereof shall be promptly (and in no event later than 30 days after entry of final judgment no longer subject to further appeal) returned to the producing party or certified as destroyed, except that the parties’ counsel shall be permitted to retain their working files on the condition that those files will remain protected. 11. Nothing herein shall preclude the parties from disclosing material designated to be Confidential Information if otherwise required by law or pursuant to a validsubpoena. 12. Notwithstanding any other provision, no document may be filed with the Clerk under seal without a further Order of this Court addressing the specific documents or portions of documents to be sealed. Any application to seal shall be accompanied by an affidavit or affidavits and a memorandum of law, demonstrating that the standards for sealing have been met and specifically addressing the applicability of Lugosch v. Pyramid Co. of Onondaga,

(2d Cir. 2006) and any other controlling authority. 13. Unless otherwise ordered, a party seeking to file an opposing party’s confidential information shall so advise the opposing party fourteen (14) days in advance specifying the precise portion of the information the party seeks to use, the general purpose thereof and any redactions to which the party does not object. Within seven (7) days thereafter, the party whose confidential information is sought to be used may make an application to seal in accordance with the first paragraph of this Order, indicating the portion or portions of the information it seeks to have sealed. 14. Nothing herein is intended to alter or modify the applicability of Rule 5.2, Fed. R. Civ. P., to this case. The redactions expressly authorized by Rule 5.2 may be made without further application to the Court. SO STIPULATED AND AGREED. Dated: August 5, 2020 Dated: August, 2020

Jamie L. Helman, Esq. Andrew T. Solomon, Esq. Sandra D. Grannum, Esq. SOLOMON & CRAMER Edward J. Scarillo, Esq. 1441 Broadway FAEGRE DRINKER BIDDLE & REATH Suite 6026 LLP New York, NY 10018 1177 Avenue of the Americas (212)-884-9102 phone 41st Floor New York, NY 10036 (212)-248-3140 Counsel for Oramed Pharmaceuticals Inc. Counsel for Raymond James & Associates, Inc.

SO ORDERED.

: im

Hon. P. Kevin Castel, U.S.D.J. Dated: August 10, 2020.

Exhibit A Agreement

I have been informed by counsel that certain documents or information to be disclosed to me in connection with the matter entitled have been designated as confidential. I have been informed that any such documents or information labeled “CONFIDENTIAL” are confidential by Order of the Court. Iherebyagreethat Iwillnotdiscloseanyinformation contained in suchdocuments toany other person. I further agree not to use any such information for any purpose other than this litigation. DATED:

Signed in the presence of:

(Attorney)